

SAMORITA HOSPITAL LIMITED
Half Yearly Financial Statements

Dear Shareholders,
We are pleased to forward herewith the unaudited Financial Statements of the company for the half year ended 31st December, 2023 as per Bangladesh Securities and Exchange Commission's notification No. SEC/CMRRCD/2008-183/Admin/03-34 dated September 27, 2009.

Statement of Financial Position (Un-audited)
As at 31st December, 2023 (Figure in Taka "000")

Particular	Notes	December, 31 2023	June, 30 2023
Assets			
Non-Current Assets			
Property, Plant & Equipment(WDV)	3	1,103,832	979,864
Right of Use Assets	4	1,596	2,395
Investment in Associate	5	5,965	5,944
Total Non-Current Assets		1,111,393	988,203
Current Assets:			
Inventories	6	23,209	20,649
Trade Receivable	7	11,593	10,048
Advance, Deposits & Prepayments	8	8,913	13,137
Advance Income Tax	9	12,684	13,528
Cash & Cash Equivalents	10	67,835	44,366
Total Current Assets		124,234	101,728
Total Assets		1,235,627	1,089,931
Equity and Liabilities			
Shareholders' Equity:			
Share Capital	11	218,009	198,190
Retained Earnings	12	120,974	121,110
Revaluation Reserve	14	753,343	636,826
Dividend Equalisation Fund	13	2,955	2,955
Total Equity		1,095,281	959,081
Non- Current Liabilities :			
Deferred Tax Liabilities	15	49,438	43,051
Lease Liability	16.01	742	742
Long Term Loan	17	18,328	18,328
Total Non- Current Liabilities		68,508	62,121
Current Liabilities :			
Trade Payable	18	34,887	31,813
Long Term Loan (Current Portion)	19	12,532	21,445
Lease Liability (current portion)	16.01	1,000	1,814
Other Payable	20	2,489	960
Provision & Accruals	21	10,300	6,372
Provision for Income Taxes	22	9,372	5,352
Unclaimed Dividend	23	1,258	973
Total Current Liabilities		71,837	68,729
Total Liabilities		140,346	130,850
Total Equity and Liabilities		1,235,627	1,089,931

Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the half year ended 31st December, 2023. (Figure in Taka "000")

	Notes	July, 2023 to December, 2023	July, 2022 to December, 2022	October, 2023 to December, 2023	October, 2022 to December, 2022
Revenue	25	207,737	170,913	88,390	87,982
Direct Expenses	26	(80,330)	(68,793)	(37,129)	(35,150)
Gross Profit		127,407	102,120	51,261	52,832
Operating Expenses:					
Administrative Expenses	27	(102,391)	(94,248)	(50,340)	(48,202)
Profit from Operation		25,015	7,872	921	4,630
Share of Profit/ (loss) of Associate	24	21	17	1	2
Financial Expenses	28	(1,885)	(2,541)	(887)	(1,222)
Non Operating Income	29	3,266	3,830	1,800	1,885
Profit before contribution to WPPF		26,417	9,178	1,835	5,295
Contribution to WPPF		(1,258)	(438)	(87)	(252)
Profit Before Tax		25,159	8,740	1,748	5,043
Income Tax Expenses		(5,477)	(2,005)	(301)	(1,050)
Current Tax	30	6,671	2,115	889	1,200
Deferred Tax	15.01	(1,194)	(110)	(588)	(150)
Profit after Tax		19,683	6,735	1,448	3,993
Total Comprehensive income		19,683	6,735	1,448	3,993
EPS		0.90	0.31	0.06	0.18


CFO


Company Secretary


Managing Director


Director


Chairman

Statement of Changes In Equity (Un-audited)
For the half year ended 31st December , 2023. (Figure in Taka "000")

Particular	Share Capital	Retained Earning	Dividend Equalisation Fund	Revaluation Reserve	Total
Balance as at July 01,2023	198,190	121,110	2,955	636,826	959,081
Transferred to Dividend Equalisation Fund		-	-		-
Total Comprehensive income	-	19,683		-	19,683
Revaluation Surplus on land				124,099	124,099
Transferred to Share Capital	19,819	(19,819)			-
Transferred to deferred tax liabilities				(7,582)	(7,582)
Balance as at December 31,2023	218,009	120,974	2,955	753,343	1,095,281
Balance as at July 01,2022	188,752	140,203	2,919	636,826	968,700
Transferred to Dividend Equalisation Fund		-	-		-
Dividend		(9,438)			(9,438)
Transferred to Share Capital	9,438	(9,438)			-
Total Comprehensive income	-	6,735	-	-	6,735
Balance as at December 31,2022	198,190	128,062	2,919	636,826	965,997

Statement of Cash Flows (Un-audited)
For the half year ended 31st December , 2023. (Figure in Taka "000")

	December,31 2023	December,31 2022
A. Cash flows from Operating Activities:		
Cash Received from Customers	208,551	175,555
Cash Paid to Suppliers & Employees	(163,698)	(148,991)
Cash generated from Operations:	44,853	26,564
Income Tax Paid	(1,807)	(459)
Net Cash from Operating Activities	43,046	26,105
B. Cash flows from Investing Activities		
Purchase of Property, Plant & Equipment	(10,318)	(18,147)
Bank Interest	286	223
FDR interest	875	1,050
Net Cash used in Investing Activities	(9,157)	(16,874)
C. Cash flows from Financing Activities		
Bank Loan paid	(10,705)	(10,530)
Unclaimed Dividend	285	(211)
Net Cash Used in Financing Activities	(10,420)	(10,741)
D. Net Cash Inflows / (outflows)	23,469	(1,510)
E. Opening Cash & Bank Balance	44,366	69,462
F. Closing Cash & Bank Balance	67,835	67,952

Additional information as per listing regulation:

Particulars	December,31 2023	June,30 2023
Net Assets Value per Share (NAV)	50.24	43.99
Earning Per Share(EPS)	0.90	0.31
Net Operating Cash Flow Per Share(NOCFPS)	1.97	1.20

Reasons of deviation in financial parameters:






Operating results:

Operating result in the reporting period has been significantly increased due to the following reasons, compared to previous corresponding period:

- Revenue has been increased by Tk. 3.68 Crore.
- Cost of direct materials has been decreased by 1.58%.
- Administrative expenses has been decreased from 55.14% to 49.29% of revenue.

Net operating cash flow per share (NOCFPS) increased from Tk. 1.20 to Tk.1.97 due to cash receipts from customers have been increased by Tk. 3.30 Crore.

d. Net Assets value (NAV) per share increased by Tk. 6.25 due to revaluation gain on land and usual business activities of the company.

 CFO
  Company Secretary
  Managing Director
  Director
  Chairman

"The details of the published half yearly financial statements can be available in the web-site of the company. The address of the web-site is www.samoritahospital.org "

Samorita Hospital Limited
Selected Notes to the Financial Statements(Un-audited)
For the half year ended 31st December , 2023.

1.00 Legal status and nature of the Company-Disclosure under IAS-1 "Presentation of Financial Statements".

1.01 Company Profile

Samorita Hospital Limited started its business from 01 February 1984 under the name and style as "M/s. Samorita Nursing Home". Then it was a partnership concern and 14 October 1985 it was converted into a Private Limited Company under the name and style as Samorita Nursing Home Ltd. Subsequently its name and style was changed and renamed as Samorita Hospital (Pvt.) Limited on 17 January 1990. Again on 23 June 1996 it was converted into a Public Limited Company under the name and style as "Samorita Hospital Limited".

The company went for public issue of share in 1996 and its shares are listed with the Stock Exchanges of Bangladesh.

1.02 Basis of preparation of Financial Statements:

These interim Financial Statements should be read in conjunction with the financial statements for the year ended 30th June, 2023 as they provide an update to previously reported information.

The Accounting Policies used are consistent with those in the Annual Financial Statements. The Financial Statements have been prepared in accordance with the applicable International Financial Reporting Standards (IFRS). The Presentation of the interim Financial Statements is consistent with the Annual Financial Statements.

1.03 Investment in associate Company:

The Company's investment in associate company is accounted for in the financial statements using the Equity Method in accordance with IAS-28 "Investment in Associates".

2.00 Specific Accounting Policies selected and applied for Significant Transactions and Events:

2.01 Accounting Convention (Measurement IASs)

The financial statements have been prepared on a going concern basis under the historical cost convention in accordance with International Financial Reporting Standards (IFRSs) therefore, do not take into consideration the effect of inflation.

2.02 Statement of compliance

The financial statements have been prepared in accordance with the applicable International Financial Reporting Standards (IFRSs), and The Companies Act 1994 and Securities & Exchange Rules 2020.

2.03 Reporting Currency and Level of Precision

The financial statements are presented in Bangladeshi Taka (BDT) which is the functional currency of the company. The amounts in these financial statements have been rounded off to the nearest integer.

2.04 Risk and Uncertainties for use of estimates in preparation of Financial Statements

The preparation of Financial Statements in conformity with the International Financial Reporting Standards requires management to make estimates and assumptions that affects the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the period reported. Actual result could differ from those estimates. Estimates are used for accounting certain items such as long term contract, provision for doubtful contracts, depreciation and amortization, Tax reserve and contingencies.

2.05 Reporting Period

The company's accounting year is July-June and this financial statements are prepared covering the period of Six months from 01 July 2023 to 31 December 2023.

2.06 Comparative Information

Comparative information has been disclosed in respect of the period in accordance with IAS-1: Presentation of Financial Statements, for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current period's financial statements.

2.07 Recognition of Property, Plant & Equipment and Depreciation

Property, plant & equipment are recognized if it is probable that future economic benefits associated with the assets will flow to the company and the cost of the assets can be reliably measured. All fixed assets are stated at cost or revaluation less accumulated depreciation as per IAS-16 "Property, Plant and Equipment". No depreciation is charged on land and land development. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes. The cost and accumulated depreciation of depreciable assets retired or otherwise disposed of are subject to elimination from the assets and accumulated depreciation and any gain or loss on such disposal will reflect in operations for the period.

2.08 Revaluation of Freehold Land

Samorita Hospital Limited revalued the freehold land on 30th September, 2023 by Basu Banerjee Nath & Co. a Chartered Accountancy firm and the details of the revaluation of Freehold Land of the Company as under:

Area of Land (Decimal)	Cost	Revaluation gain (As per revaluation of the year 2013)	Book value as on 30th June,2022	Current value as per revaluation on 30th Sept, 2023.	Revaluation gain
28.66	30,182,041	664,617,959	694,800,000	706,357,727	11,557,727
3.60	33,079,000	-	33,079,000	62,021,477	28,942,477
6.80	32,367,190	-	32,367,190	115,965,682	83,598,492
39.06	95,628,231	664,617,959	760,246,190	884,344,886	124,098,696

The Board of Directors adopted the valuation report in its 203rd meeting held on October 28, 2023 unanimously.

2.09 Inventories

Inventories comprise various Medicine, Material for Pathology, X-Ray, OT, Cleaning Materials, Linens, Printing and Stationery, Materials for ECG and USG. They are stated at the lower of cost and net realizable value in accordance with IAS -2 "Inventories" after making due allowances for any obsolete or slow moving items.

2.10 Financial Instruments

Financial Assets

Trade Receivable

Trade receivables are recognized and stated at original invoiced amounts and carried at anticipated realizable values.

Cash and Cash Equivalent

It includes cash in hand and cash at bank which were held and available for use by the company without any restriction and there was insignificant risk of change in value of these current assets.

2.11 Creditors and Accrued Expenses

Liabilities are recognized for amounts to be paid in future for goods and services received, whether or not billed by the supplier.

2.12 Taxation

Income tax expenses comprise current and deferred taxes. Income taxes are recognized in statement of profit or loss and other comprehensive income except to the extent that relates to items recognized directly in equity or in other comprehensive income. The Company is a publicly traded Company. As per the Income Tax Act 2023, provision for Tax has been made at the existing rate of 22.50% in respect of business income.

Current Tax

Provision for current income tax has been made as per prescribed rate in the Finance Act, 2023 on the accounting profit made by the company after considering some of the add backs to income and disallowances of expenditure as per income tax laws in compliance with IAS-12: "Income Taxes".

Deferred Tax

Deferred tax liabilities are the amount of income taxes payable in future periods in respect of taxable temporary differences. Deferred tax assets are the amount of income taxes recoverable in future periods in respect of deductible temporary differences. Deferred tax assets and liabilities are recognized for the future tax consequences of timing differences arising between the carrying values of assets, liabilities, income and expenditure and their respective tax bases. Deferred tax assets and liabilities are measured using tax rates and tax laws that have been enacted or substantially enacted at the balance sheet date. The impact on the account of changes in the deferred tax assets and liabilities has also been recognized in the statement of comprehensive income as per IAS-12: "Income Taxes".

2.13 Revenue Recognition

In accordance with the provisions of the IFRS-15: "Revenue from Contracts with Customers"; revenue from contracts with customers represents the amount that reflects the considerations to which entity expects to be entitled in exchange for goods supplied and service provided to customers during the year. Revenue from contracts with customers is recognized in the statement of profit or loss and other comprehensive income when the performance obligation (supply of promised goods and services) is satisfied. Performance obligation is satisfied at a point in time when customer obtains the control of goods and services. Revenue has been recognized at the time of invoice made for the services rendered by the company.

Interest income

The interest income is recognized on accrual basis as agreed terms and conditions with the banks.

Non operating income

Non operating income are recognized at the time of receive of money from other purpose than the normal course of business of the Company.

2.14 Earnings Per Share (EPS)

The Company calculates Earnings Per Share (EPS) in accordance with IAS -33 "Earnings Per Share". which has been shown on the face of the statement of comprehensive income. This has been calculated by dividing the basic earnings by the number of ordinary shares outstanding during the year.

2.15 Statement of Cash Flows

Statement of Cash Flows is prepared principally in accordance with IAS -7 "Statement of Cash Flows" and the cash flow from the operating activities have been presented under the direct method as prescribed by the Securities and Exchange Rules 1987 and considering the provision of Paragraph 19 of IAS -7 which provides that enterprise are encouraged to report "Cash Flow from the Operating Activities using the direct Method".

2.16 Additional information on Financial Statements:

Compliance with International Financial Reporting Standards (IFRSs)

The financial statements have been prepared in compliance with requirements of IFRSs adopted by the Institute of Chartered Accountants of Bangladesh (ICAB).

2.17 Foreign Exchange Earned and Payment

During the period the Company has not earned or made payment any amount of foreign currency.

2.18 Provisions, Contingent Liabilities and Contingent Assets (IAS-37)

There are certain pending tax claims made against the Company, which will be settled through the legal process in due course. These are being vigorously defended by the company. The management has not considered it necessary at the reporting date to make provisions in the financial statements in respect of any of these claims.

Accounting Year	Assessment Year	Tax Declared	Assessment by Tribunal	Tax paid	Tax Liability/ Claimed Amount	Present Status
2012-2013	2013-2014	13,623,217	12,843,912	13,723,217	(879,305)	Case is Pending at High court
2013-2014	2014-2015	11,669,566	15,188,234	12,879,566	2,308,668	Case is Pending at High court
2014-2015	2015-2016	11,473,176	12,616,428	11,773,176	843,252	Case is Pending at Tribunal

2015-2016	2016-2017	10,372,742	12,904,058	11,482,742	1,421,316	Case is Pending at High court
2016-2017	2017-2018	13,918,465	14,450,494	14,433,465	17,029	Case is Pending at High court
2017-2018	2018-2019	8,675,427	8,893,836	9,747,897	(854,061)	As per Assessment order
2018-2019	2019-2020	11,453,108	-	11,453,108	-	Return Submitted Under Section 82BB
2019-2020	2020-2021	3,678,790	13,143,637	9,329,484	3,814,153	Case is Pending at 2nd appeal (Tribunal)
2020-2021	2021-2022	13,632,068	16,541,199	11,246,630	5,294,569	Preparations are underway for sub-mission of appeal (Tribunal)
2021-2022	2022-2023	5,154,507	-	6,287,425	(1,132,918)	Return Submitted but Assessment not yet done
2022-2023	2023-2024	2,650,892		2,837,024	(186,132)	Return not Submitted
Total		106,301,958	106,581,798	115,193,734	10,646,571	

2.19 Impairment of Assets (IAS-36)

No facts and circumstances indicate that the company's assets may be impaired. Hence, no evaluation of recoverability of assets was performed.

2.20 Employee Benefits (IAS-19)

The Company provides short term employee benefits to its eligible employees in the form of incentive which charged as revenue expenditure in the period to which the incentive relates.

2.21 Workers' Profit Participation and Welfare Fund:

The Company recognizes a provision for Workers' Profit Participation Fund @ 5% of net profit before Taxes in accordance with Bangladesh Labour Law 2006.

As at
December, 31
2023

As at
June, 30
2023

Figure in Taka"000"

3. Property, Plant & Equipment:

Cost/Revaluation:

Land	884,346	760,247
Building	256,481	254,281
Equipments	173,570	171,170
Furniture & Fixture	29,719	29,562
Lift	21,405	17,355
Generator	7,630	7,630
Medical Oxygen System	30,078	30,078
Others	42,586	40,076
	1,445,815	1,310,399

Less: Accumulated Depreciation

Written Down Value

4.Right of Use Assets

Cost	4,790	4,790
Less: Amortisation	3,194	2,395
	1,596	2,395

5. Investment in Associate:

Opening Balance	5,944	5,829
Share of income / (loss) of Associate (note.24)	21	39
Prior year adjustment	-	76
	5,965	5,944

Share of income of Associate has been shown on the basis of unaudited report of the Imaging services Ltd. (Associate company) for the 2nd quarter ended December 31, 2023 in accordance with IAS-28.

As at
December, 31
2023

As at
June, 30
2023

Figure in Taka"000"

6. Inventories:

Medical Services	4,918	4,725
Diagnostics	6,851	3,806
Pharmacy	11,440	12,118
	23,209	20,649

7. Trade Receivable:

Receivable from Indoor Patient	7,011	6,003
Receivable from Outdoor Patient	1,068	698
Receivable from Institution	3,000	2,890
Rent Receivable	239	190
Receivable from FDR Interest	275	267
	11,593	10,048

8. Advance, Deposits & Prepayments :

Advance for Work & others	2,306	3,216
Advance for Capital Item	2,000	3,000
Security Money & Deposit	1,538	1,538
Prepayments	3,069	5,383
	8,913	13,137

9. Advance Income Tax

Opening Balance	13,528	15,788
Add: Paid during the year	1,807	2,895
	15,335	18,683
Less: Adjusted during the year	2,651	5,155
Closing Balance	12,684	13,528

10. Cash & Cash Equivalents :

Cash in hand	2,388	1,658
Union Bank FDR	22,541	20,000
Cash at bank	42,906	22,708
	67,835	44,366

11. Issued, Subscribed and Paid up Capital:

2,18,00,897 shares @ Tk. 10.00 each	218,009	198,190
-------------------------------------	----------------	----------------

12. Retained Earnings

Opening Balance	121,110	140,203
Less: Transfer to Share Capital	19,819	9,438
Less: Dividend Paid	-	9,438
Add: Prior year adjustment of Investment of Associate	-	76
Less: Prior Year Adjustment	-	978
	101,291	120,425
Add: Total Comprehensive Income for the year	19,683	721
	120,974	121,146
Less: Transferred to Dividend Equalisation Fund	-	36
	120,974	121,110

13. Dividend Equalisation Fund:

Opening	2,955	2,919
Add: Addition	-	36
Closing	2,955	2,955

14. Revaluation Reserve

Opening Balance	636,826	636,826
Add: Revaluation gain of land	124,099	-
Less: Transferred to Deferred tax Liabilities (note 14.01)	7,582	-
	753,343	636,826

14.01. Movement in deferred tax liability

Closing Balance	35,374	27,792
Opening Balance	27,792	27,792
	7,582	-

15. Deferred Tax Liabilities

Opening Balance	43,051	43,323
Add: Provision made during the year for temporary difference (Note: 15.01)	(1,194)	(272)
Add: Transferred from Revaluation Reserve (note 14.01)	7,582	-
	49,438	43,051

15.01 Deferred tax liability is arrived at as follows :

i. Deferred tax on PPE

Carrying amount (Accounting base)	315,116	315,246
Carrying amount (Tax base)	251,823	247,427
Taxable/(deductible) temporary difference	63,293	67,819
Permanent differences	415	415
Net Taxable/(deductible) temporary difference	62,878	67,404
Deferred tax Liability/(Assets) @ 22.50%	14,148	15,166

	As at December, 31 2023	As at June, 30 2023
Figure in Taka"000"		
ii. Deferred tax on Right of Use Assets		
Carrying amount (Accounting base)	1,596	2,395
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	1,596	2,395
Deferred tax Liability/(Assets) @ 22.50%	359	539
iii. Deferred tax on Lease Liabilities		
Carrying amount (Accounting base)	742	742
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	(742)	(742)
Deferred tax Liability/(Assets) @ 22.50%	(167)	(167)
iv. Deferred tax on share of profit on Investments		
Carrying amount (Accounting base)	5,963	5,944
Carrying amount (Tax base)	7,335	7,335
Taxable/(deductible) temporary difference	(1,372)	(1,391)
Deferred tax Liability/(Assets) @ 20%	(274)	(278)
v. Deferred tax on revaluation of property, plant and equipment:		
Carrying amount (Accounting base)	884,345	694,800
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	884,345	694,800
Deferred tax Liability/(Assets) @ 4%	35,374	27,792
Total deferred tax liability as on Dec 31, 2023	49,439	43,052
Movement of Deferred Tax on PL Items		
Opening Deferred Tax Liability	15,260	15,531
Expense/(Income) during the year	(1,194)	(271)
Closing Deferred Tax Liability	14,065	15,260
16 Lease Liability		
Opening Balance	2,556	4,079
Addition during the year	-	-
Finance costs during the year	93	292
Payments during the year	(907)	(1,815)
Closing Liability	1,742	2,556
16.01 Lease Liability		
Lease Liability-Current	1,000	1,814
Lease Liability-Non Current	742	742
	1,742	2,556
17. Long Term Loan		
a. Principal Amount		
Opening Balance	39,773	55,000
Add: Addition during the year	-	-
	39,773	55,000
Less: Repayment	8,913	15,227
Total	30,860	39,773
b. Interest Amount		
Opening Balance	-	1,551
Add: Addition during the year	1,792	4,332
	1,792	5,883
Less: Repayment	1,792	5,883
Total	-	-
Closing Balance	30,860	39,773
Less: Long Term Loan (Current Portion)	12,532	21,445
Total	18,328	18,328
All fixed and floating assets are mortgaged against long term loan.		
18. Trade Payable:		
Advance Receipt from Patient	1,419	1,076
Advance Receipt from MTB & Others	449	539
Current Liability for Expenses	839	733
Current Liabilities for Supply	16,949	15,493
Workers profit participation fund (note 18.01)	15,231	13,973
	34,887	31,813

As at
December, 31
2023

As at
June, 30
2023

Figure in Taka"000"

18.01. Workers profit participation fund :

Opening Balance	13,973	14,770
Less: Paid During the year	-	2,377
	13,973	12,393
Add: Provision made during the year	1,258	155
Add: Interest Charged for the year	-	1,425
	<u>15,231</u>	<u>13,973</u>

19. Long Term Loan (Current Portion)

Closing Balance	<u>12,532</u>	<u>21,445</u>
-----------------	---------------	---------------

20. Other Payables

Suppliers & Others Vat	1226	514
Suppliers & Others Tax	995	446
Managing Directors Salary Tax	268	-
	<u>2,489</u>	<u>960</u>

21. Provision & Accruals:

Utility Bills	1,373	1,912
Salary & Allowance	8,766	4,156
Others	161	304
	<u>10,300</u>	<u>6,372</u>

22. Provision for Income Taxes

Opening Balance	5,352	7,856
Less: Adjusted during the year (Note-9)	2,651	5,155
	2,701	2,701
Less: Paid During the Year	-	-
	2,701	2,701
Add: Provision made during the year	6,671	2,651
	<u>9,372</u>	<u>5,352</u>

23. Unclaimed Dividend

Opening Balance	973	1,172
Add : Addition during the year	285	982
	1,258	2,154
Less: Capital Market Stablization Fund	-	1,172
Less: Paid during the year	-	9
	<u>1,258</u>	<u>973</u>

The Above amount of Tk.973,000 has been unclaimed for the financial year 2020-2021. As per BSEC Directive No. BSEC/CMRRCD/2021-386/03 dt.January 14, 2021 the amount shall be payable to CMFS as soon as the expiry of 3 years. Hence the amount shall be payable to CMSF on 29th December, 2024.

December, 31
2023

December, 31
2022

Figure in Taka"000"

24. Share of Profit / (loss) of Associate :

Net profit/ (loss) of Associate company	47	37
Share of Profit/ (loss) of Associate company (45% of Tk. 47)	21	17

25. Revenue

Medical Services	96,633	75,513
Diagnostic	55,175	45,954
Pharmacy	55,929	49,446
	<u>207,737</u>	<u>170,913</u>

26. Direct Expenses:

Medical Services	17,328	15,082
Diagnostic	20,697	17,371
Pharmacy	42,305	36,340
	<u>80,330</u>	<u>68,793</u>

December, 31
2023

December, 31
2022

Figure in Taka"000"

27. Administrative Expenses:

Salary & Allowance	54,468	50,146
Managing Director's Salary	4,140	4,116
Utility Bills	11,193	9,107
Repair	2,159	4,461
Depreciation	11,449	11,254
Depreciation on Right of Use Assets	798	798
Printing	1,086	1,034
Bad debt	380	117
Others	16,718	13,215
	102,391	94,248

28. Financial Expenses

Interest on Term Loan	1,792	2,378
Interest on Lease Liability	93	163
	1,885	2,541

29. Non Operating Income

Rent Received	1,590	1,741
FDR Interest	883	1,079
Bank Interest	286	223
Referral Income	327	327
Others	180	460
	3,266	3,830

30. Current year's Tax

i. Regular Tax

Net profit before tax as per profit & loss Account	25,159	8,740
Less: Profit/(Loss) from Investments	21	17
	25,138	8,723

Add: Items of charges to be considered separately:

Accounting depreciation	11,449	11,254
Depreciation on RoU Assets	798	798
Finance Cost on Lease Liabilities	93	163
	12,340	12,215

Less: Admissible items:

Payments for Leases	907	907
Tax depreciation	6,922	10,634
	7,829	11,541

Total business income during the year

	29,649	9,397
Regular Tax on business income @ 22.5%	6,671	2,115
	6,671	2,115

31. Special disclosure as per notification No. BSEC/CMRRCD/2006-158/208/Admin/81 is as under:

a) Detailed break-up of shareholders equity:

	As at December, 31 2023	As at June, 30 2023
Share Capital (note- a.01)	218,009	198,190
Retained Earnings (note- a.02)	120,974	121,110
Revaluation Reserve (note- a.03)	753,343	636,826
Dividend Equalisation Fund	2,955	2,955
Total Equity	1,095,281	959,081

Figure in Taka"000"

a.01 , Paid-up capital:

Type of Share	No. of Shares	Face value	Issu Date	Figure in Taka"000"	
Ordinary Share	6,000	10.00	10/11/1997	60,000	60,000
Bonus Share	600	10.00	23/04/2005	6,000	6,000
Bonus Share	990	10.00	26/01/2010	9,900	9,900
Bonus Share	1,214	10.00	08/02/2012	12,140	12,140
Bonus Share	1,584	10.00	24/01/2013	15,844	15,844
Bonus Share	3,117	10.00	26/01/2014	31,170	31,170
Bonus Share	1,351	10.00	07/01/2015	13,510	13,510
Bonus Share	1,486	10.00	26/12/2016	14,860	14,860
Bonus Share	1,634	10.00	28/12/2017	16,340	16,340
Bonus Share	899	10.00	05/01/2020	8,988	8,988
Bonus Share	944	10.00	09/01/2023	9,438	9,438
Bonus Share	1,982	10.00	15/01/2024	19,819	-
Total: 21,800,897 shares @ Tk. 10.00 each				218,009	198,190

a.02 , Retained Earnings

Opening Balance	121,110	140,203
Less: Dividend Paid	-	9,438
Less: Transfer to Share Capital	19,819	9,438
Add: Prior year adjustment of Investment of Associate	-	76
Less: Prior Year Adjustment	-	978
	101,291	120,425
Add: Total Comprehensive Income for the year	19,683	721
	120,974	121,146
Less: Transferred to Dividend Equalisation Fund	-	36
Retained Earnings	120,974	121,110

As at
December, 31
2023

As at
June, 30
2023

Figure in Taka"000"

a.03, Revaluation Reserve

Opening Balance	636,826	636,826
Add: Revaluation gain of land	124,099	-
Less: Transferred to Deferred tax Liabilities (note 14.01)	7,582	-
	753,343	636,826

b) Net Asset Value Per Share (NAV)

Total Assets	1,235,627	1,089,931
Less Total liabilities :	140,346	130,850
Non Current Liabilities	68,508	62,121
Current Liabilities	71,837	68,729
Net Assets:	1,095,281	959,081
Number of outstanding shares at the year end	21,801	21,801
Net Asset Value Per Share (NAV)	50.24	43.99

December, 31
2023

December, 31
2022

Figure in Taka"000"

c) Basic and diluted Earnings Per Share:**Basic Earning Per Share:**

Profit Attributable to ordinary shareholders	19,683	6,735
Number of outstanding shares at the year end	21,801	21,801
Basic Earning per Share (EPS)	0.90	0.31

Diluted Earning Per Share:

Diluted EPS is determined by adjusting the Profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there was no potential dilutive ordinary share during the relevant period.

d) Net operating cash flows per share (NOCFPS)

Net Cash from Operating Activities	43,046	26,105
Number of outstanding shares at the year end	21,801	21,801
Net operating cash flows per share (NOCFPS)	1.97	1.20

e) Reconciliation of Net profit with Cash Flows from Operating Activities

For the half year ended December 31, 2023

Particulars	December, 31 2023	December, 31 2022
	Figure in Taka"000"	
Profit Before Tax	25,159	8,740
Depreciation	12,247	12,052
Bad debt	380	117
(Gain) / Loss on Disposal	-	-
FDR Interest	(883)	(1,079)
Bank Interest	(286)	(223)
Investment Income (Share of (Profit) /Loss of Associate)	(21)	(17)
Financial Charges	1,885	2,541
Payment for lease	(907)	(907)
(Increase)/Decrease in Inventories	(2,560)	(7,990)
(Increase)/Decrease in Trade and other receivable	(1,537)	(259)
(Increase)/Decrease in Advance, Deposits & Prepayment	3,224	1,605
Increase/(Decrease) in Trade Payable	1,816	8,790
Increase/(Decrease) in other Payable	1,529	2,182
Increase/(Decrease) in Provision & accruals	3,549	573
Increase/(Decrease) in WPPF	1,258	438
Cash Flows from operation	<u>44,853</u>	<u>26,564</u>
Tax Paid	<u>(1,807)</u>	<u>(459)</u>
	<u><u>43,046</u></u>	<u><u>26,105</u></u>

32. Related Party Disclosures (IAS-24):

as on 31st December 2023 (Figure in Taka "000")

SL.No	Particulars	Nature of Relation	Basis of transactions	Total Transaction Value	Outstanding
1.00	Nurse Hostel	Mrs. Latifa Haroon, W/O Dr.A B M Haroon	Space rent as per contract	907	-
2.00	The Imaging Services Ltd.	Associate company	Space rent as per contract	504	229
3.00	Purabi General Insurance Company Limited	Common director	Insurance Premium as per contract	160	-
4.00	M.H. Samorita Hospital & Medical College	Common director	Pathology Test as per negotiation	859	873

December, 31 2023	June, 30 2023
Figure in Taka"000"	

33. Disclosure of key management personnel compensation:

Detailed disclosure regarding the compensation packages of key management personnel is presented below.

Key management are those persons having authority and responsibility for planning, Directing and controlling the activities of the company.

i) Remuneration and Meeting fees for Non-executive directors

Remuneration & Other benefits	-	-
Board meeting fees	232	440
	<u>232</u>	<u>440</u>


ii) Compensation of key management personnel

a) Short-term employee benefits	6,227	17,078
b) Post-employment benefits	-	-
c) Other long-term benefits	-	-
d) Termination benefits	-	-
e) Share-based payment	-	-
	<u>6,227</u>	<u>17,078</u>


Short term employee benefits consisted of salary, bonus, medical allowance, housing, cars, fees or subsidized goods or services for key management personnel.

Key management personnel includes Managing Director, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance, Head of Administration and Human Resources and Chief Medical Officer.


C F O


Company Secretary


Managing Director


Director


Chairman